Disclosure statement
PMcG is and REF was involved in teaching therapeutics. Both have been members of the Clinical Sub-Committee of the British Pharmacological Society which has been involved in the Prescribing Safety Assessment (PSA) from its inception. PMcG is a member of the PSA Standard Setting Group. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
Additional information
Funding
Notes on contributors
Patricia McGettigan
Patricia McGettigan, BSc(Pharm), MD, is Associate Professor of Clinical Pharmacology and Medical Education at Queen Mary University of London.
Robin E. Ferner
Robin E. Ferner, MSc, MD, is Emeritus Professor of Clinical Pharmacology at the University of Birmingham.